Adaptive Designs for Clinical Trials of Drugs and Biologics; Guidance for Industry; Availability

Özet

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Adaptive Designs for Clinical Trials of Drugs and Biologics." This guidance provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications on the appropriate use of adaptive designs for clinical trials to provide evidence of the effectiveness and safety of a drug or biological product. The guidance describes important principles for designing, conducting, and reporting the results from an adaptive clinical trial. This guidance finalizes the draft guidance entitled "Adaptive Designs for Clinical Trials of Drugs and Biologics" issued in October 2018. FDA is also announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.